hsa_circ_0004276 inhibits osteogenic differentiation of bone marrow mesenchymal stem cells and exacerbates postmenopausal osteoporosis through interaction with ELAVL1.

OBJECTIVE

The aim of this study was to investigate the potential of hsa_circ_0004276 as a diagnostic marker for Postmenopausal Osteoporosis (PMO) and its potential interaction with the RNA-binding protein ELAV-like RNA binding protein-1 (ELAVL1).

METHODS

The circRNA expression profiles obtained from the GSE159121 dataset were used to screen for differentially expressed circRNAs in patients with PMO. hsa_circ_0004276 was further analyzed and validated for its circular structure using a bioinformatics website, actinomycin D, and RNase R assays. Serum samples from 115 PMO patients and 103 healthy controls were collected. RT-qPCR and western blot were applied to assess hsa_circ_0004276 and ELAVL1. The effects of hsa_circ_0004276 and ELAVL1 on osteogenic differentiation of human Bone Marrow Mesenchymal Stem Cells (BMSCs) were investigated by in vitro experiments.

RESULTS

hsa_circ_0004276 was highly expressed in PMO patients and negatively correlated with low bone mineral density. hsa_circ_0004276 had high specificity and sensitivity for the diagnosis of PMO. hsa_circ_0004276 significantly interacted with ELAVL1. During BMSC osteogenic differentiation, hsa_circ_0004276 knockdown significantly increased calcium deposition and ALP activity, while hsa_circ_0004276 overexpression showed the opposite effect. In addition, ELAVL1 expression was reduced in PMO patients and positively correlated with hsa_circ_0004276.

CONCLUSION

hsa_circ_0004276 regulates osteogenic differentiation of BMSCs through its interaction with ELAVL1 in PMO pathogenesis. This finding provides a new perspective for the study of the molecular mechanism of PMO and a theoretical basis for the development of new therapeutic targets.